• Something wrong with this record ?

CaMKIIα hub ligands are unable to reverse known phenotypes in Angelman syndrome mice

SJ. Gauger, MEK. Lie, I. Wallaard, Y. Tian, A. Marek, B. Frølund, GM. van Woerden, Y. Elgersma, BR. Kornum, P. Wellendorph

. 2025 ; 136 (1) : e14112. [pub] -

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25002855

Grant support
NNF19SA0057841 Novo Nordisk Foundation
R277-2018-260 Lundbeck Foundation

Angelman Syndrome (AS) is a neurodevelopmental disorder caused by the loss of function of ubiquitin-protein ligase E3A (UBE3A), resulting in marked changes in synaptic plasticity. In AS mice, a dysregulation of Ca2+/calmodulin-dependent protein kinase II alpha (CaMKIIα) was previously described. This has been convincingly validated through genetic rescue of prominent phenotypes in mouse cross-breeding experiments. Selective ligands that specifically stabilize the CaMKIIα central association (hub) domain and affect different conformational states in vitro are now available. Two of these ligands, 3-hydroxycyclopent-1-enecarboxylic acid (HOCPCA) and (E)-2-(5-hydroxy-2-phenyl-5,7,8,9-tetrahydro-6H-benzo[7]annulen-6-ylidene)acetic acid (Ph-HTBA), confer neuroprotection after ischemic stroke in mice where CaMKIIα is known to be dysregulated. Here, we sought to investigate whether pharmacological modulation with these prototypical CaMKIIα hub ligands presents a viable approach to alleviate AS symptoms. We performed an in vivo functional evaluation of AS mice treated for a total of 14 days with either HOCPCA or Ph-HTBA (7 days pre-treatment and 7 days of behavioural assessment). Both compounds were well-tolerated but unable to revert robust phenotypes of motor performance, anxiety, repetitive behaviour or seizures in AS mice. Biochemical experiments subsequently assessed CaMKIIα autophosphorylation in AS mouse brain tissue. Taken together our results indicate that pharmacological modulation of CaMKIIα via the selective hub ligands used here is not a viable treatment strategy in AS.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002855
003      
CZ-PrNML
005      
20250206103915.0
007      
ta
008      
250121s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bcpt.14112 $2 doi
035    __
$a (PubMed)39668309
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Gauger, Stine J $u Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000230170962
245    10
$a CaMKIIα hub ligands are unable to reverse known phenotypes in Angelman syndrome mice / $c SJ. Gauger, MEK. Lie, I. Wallaard, Y. Tian, A. Marek, B. Frølund, GM. van Woerden, Y. Elgersma, BR. Kornum, P. Wellendorph
520    9_
$a Angelman Syndrome (AS) is a neurodevelopmental disorder caused by the loss of function of ubiquitin-protein ligase E3A (UBE3A), resulting in marked changes in synaptic plasticity. In AS mice, a dysregulation of Ca2+/calmodulin-dependent protein kinase II alpha (CaMKIIα) was previously described. This has been convincingly validated through genetic rescue of prominent phenotypes in mouse cross-breeding experiments. Selective ligands that specifically stabilize the CaMKIIα central association (hub) domain and affect different conformational states in vitro are now available. Two of these ligands, 3-hydroxycyclopent-1-enecarboxylic acid (HOCPCA) and (E)-2-(5-hydroxy-2-phenyl-5,7,8,9-tetrahydro-6H-benzo[7]annulen-6-ylidene)acetic acid (Ph-HTBA), confer neuroprotection after ischemic stroke in mice where CaMKIIα is known to be dysregulated. Here, we sought to investigate whether pharmacological modulation with these prototypical CaMKIIα hub ligands presents a viable approach to alleviate AS symptoms. We performed an in vivo functional evaluation of AS mice treated for a total of 14 days with either HOCPCA or Ph-HTBA (7 days pre-treatment and 7 days of behavioural assessment). Both compounds were well-tolerated but unable to revert robust phenotypes of motor performance, anxiety, repetitive behaviour or seizures in AS mice. Biochemical experiments subsequently assessed CaMKIIα autophosphorylation in AS mouse brain tissue. Taken together our results indicate that pharmacological modulation of CaMKIIα via the selective hub ligands used here is not a viable treatment strategy in AS.
650    _2
$a zvířata $7 D000818
650    12
$a Angelmanův syndrom $x farmakoterapie $x genetika $7 D017204
650    12
$a proteinkinasa závislá na vápníku a kalmodulinu typ 2 $x metabolismus $7 D054732
650    12
$a fenotyp $7 D010641
650    _2
$a myši $7 D051379
650    12
$a modely nemocí na zvířatech $7 D004195
650    _2
$a ligandy $7 D008024
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a chování zvířat $x účinky léků $7 D001522
650    _2
$a ubikvitinligasy $x metabolismus $x genetika $7 D044767
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a neuroprotektivní látky $x farmakologie $7 D018696
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mozek $x účinky léků $x metabolismus $7 D001921
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lie, Maria E K $u Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000219479125
700    1_
$a Wallaard, Ilse $u Department of Clinical Genetics, Center of Expertise for Neurodevelopment (ENCORE), Rotterdam, The Netherlands $1 https://orcid.org/0000000162493339
700    1_
$a Tian, Yongsong $u Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000170849083
700    1_
$a Marek, Aleš $u Institute of Organic Chemistry and Biochemistry, The Czech Academy of Sciences, Prague 6, Czech Republic $1 https://orcid.org/0000000190318263 $7 xx0160473
700    1_
$a Frølund, Bente $u Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000154766288
700    1_
$a van Woerden, Geeske M $u Department of Clinical Genetics, Center of Expertise for Neurodevelopment (ENCORE), Rotterdam, The Netherlands $u Department of Neuroscience, Center of Expertise for Neurodevelopment (ENCORE), Rotterdam, The Netherlands $1 https://orcid.org/0000000324929239
700    1_
$a Elgersma, Ype $u Department of Neuroscience, Center of Expertise for Neurodevelopment (ENCORE), Rotterdam, The Netherlands $1 https://orcid.org/0000000237581297
700    1_
$a Kornum, Birgitte R $u Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000225159451
700    1_
$a Wellendorph, Petrine $u Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000254558013
773    0_
$w MED00007578 $t Basic & clinical pharmacology & toxicology $x 1742-7843 $g Roč. 136, č. 1 (2025), s. e14112
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39668309 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206103911 $b ABA008
999    __
$a ok $b bmc $g 2262947 $s 1238862
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 136 $c 1 $d e14112 $e - $i 1742-7843 $m Basic & clinical pharmacology & toxicology $n Basic Clin Pharmacol Toxicol $x MED00007578
GRA    __
$a NNF19SA0057841 $p Novo Nordisk Foundation
GRA    __
$a R277-2018-260 $p Lundbeck Foundation
LZP    __
$a Pubmed-20250121

Find record

Citation metrics

Archiving options